Umbilical cord stem cells are donor cells taken from tissue left over after a healthy birth, processed in a lab, then sold to you frozen in a vial. In the guides we publish here, this is the source patients understand least and get sold most, because a donated cord sounds cleaner and younger than drawing marrow out of your own pelvis. No umbilical cord product is FDA approved for joints, pain, or an IV drip, and the most important question about the vial is whether anything in it is still alive.
This pairs with our guide to mesenchymal stem cells, the cell type these products are sold on, and with where stem cells come from if you want the three sources side by side.
What Umbilical Cord Stem Cells Are
Umbilical cord stem cells are mesenchymal stem cells (MSCs) harvested from the cord and its surrounding tissue after delivery, from a donor who agreed to give it. Nobody is harmed to collect them. The cord is medical waste otherwise, which is why the supply is large and why the marketing leans on words like “ethical” and “newborn”.
The cells are allogeneic, meaning they came from someone else. That is the whole difference between this and a BMAC procedure or a fat harvest, where the cells are yours and go back in the same day. Donor cells have to be screened, processed, frozen, shipped, and thawed before they reach you. Every one of those steps is a place the product can be handled well or badly, and you are not in the room for any of them.
Cord Blood, Cord Tissue, and Wharton’s Jelly Are Different Products
Three different things get sold under the same “umbilical cord” heading, and the label on the vial tells you which one you are buying.
- Cord blood is the blood left in the cord and placenta. It is rich in blood-forming (hematopoietic) stem cells, and it is the only one of the three with FDA-approved uses.
- Cord tissue is the cord itself, a source of mesenchymal stem cells rather than blood-forming ones.
- Wharton’s jelly is the gelatinous connective tissue inside the cord that cushions the blood vessels. Research comparing the cord’s compartments found Wharton’s jelly gives the best yield of usable mesenchymal stem cells, which is why clinic menus name it specifically.
Clinics use the three terms loosely in marketing. Ask which one is in the vial, then ask what the label says, because a “cord blood” injection for a knee is being sold outside even the narrow use cord blood is approved for.
Why Clinics Push Donor Cord Cells
Cord products are easier to sell than your own cells for three practical reasons.
- No harvest. You skip the marrow needle or the liposuction, so the visit is a short IV or a single injection.
- Age. Newborn tissue yields more cells per gram than a 65-year-old’s marrow, and clinics use that fact to imply the treatment works better. Cell count and clinical benefit are not the same thing, and the trials have not shown the second one follows from the first.
- Volume. A single donated cord can be split into many doses, so a clinic can run cord infusions all day without a procedure room.
Volume is the business reason, and it explains why cord products dominate the IV “stem cell drip” market for conditions with no local target at all.
The Live Cell Question to Ask First
Ask the clinic for the viability report on the exact lot they plan to use, and read the number yourself. The most thorough published testing of commercial birth-tissue products came back empty. A 2020 study in the journal Cartilage ran the full proteome on nine commercial birth-tissue products from four manufacturers, covering amniotic membrane, umbilical cord, amniotic fluid and chorion. The researchers identified 919 proteins across them and found no live cells and no growth factors in any of the nine.
A frozen product can still contain useful structural proteins. It cannot deliver the living cells the sales pitch describes, and those living cells are the whole basis for the claim that the injection repairs tissue. If the clinic cannot produce a post-thaw viability figure for the lot, you are paying stem cell prices for a mix of proteins.
Where This Sits with the FDA
Cord products used for joints, pain, autism, or anti-aging are unapproved drugs, and the FDA has said so in writing to the companies selling them. The approved list includes cord blood products licensed for rebuilding the blood and immune system in people with disorders affecting blood production. Arthritis is not on that list, and neither is an IV infusion for fatigue.
In September 2019 the FDA warned Stemell, Inc. for distributing unapproved umbilical cord blood and cord products, citing deficient donor eligibility practices, unvalidated manufacturing, and inadequate aseptic processes. The FDA’s stated concern was that the products could carry viruses or bacteria, and that is a different risk from a treatment simply not working. Our FDA status guide explains the exemption clinics claim and how to check a specific product against it.
The 2018 Liveyon Contamination Outbreak
The documented harm from these products has been infection. Rejection of the donor cells was never the problem. In 2018 the CDC documented infections in 12 patients across Texas, Florida and Arizona after they received umbilical cord blood products processed by Genetech, Inc. and distributed by Liveyon, LLC. The infections included bloodstream infections, joint infections and epidural abscesses. All 12 patients were hospitalized, three of them for a month or longer, and cultures from unopened vials grew E. cloacae, C. freundii, E. coli and E. faecalis.
Every one of those patients had been treated for a nonhematopoietic problem, mostly pain or orthopedic conditions. The product was recalled that September. A donor product carries a manufacturing risk your own cells do not. No clinic can screen for a contaminant that entered the vial in someone else’s lab. Our safety guide covers the wider risk picture across sources.
Cord Injections and Cord Blood Banking Are Different Decisions
What we see readers get wrong most often is treating these as one topic. Banking your newborn’s cord blood is a decision about storage, insurance against a future diagnosis, and annual fees, and we cover it in the cord blood banking guide. Buying a donor cord injection for your knee at 58 is a purchase of an unapproved product today. Both decisions involve the same tissue, but they turn on different evidence and different amounts of money, so a clinic’s cord-banking talking points do not transfer to a knee injection.
Who This Is Not For
Skip a cord product entirely if you are treating a single joint and can get your own cells. A same-day BMAC or fat-derived procedure keeps the manufacturing inside one room and one afternoon, and it removes the donor-processing risk that produced the 2018 outbreak. Skip it too if you are being offered an IV infusion for a systemic condition like fatigue, autism, or aging, where there is no approved product, no target tissue, and no trial evidence supporting the sale.
What Would Change Our Answer
Three things would move this from caution to a real recommendation. An FDA-licensed cord-derived product for an orthopedic or systemic use would change it fastest, because approval brings manufacturing oversight with it. Consistent post-thaw viability reporting, published per lot rather than promised verbally, would change the live-cell problem. Placebo-controlled trials showing that donor cord cells beat your own cells for the same condition would change the choice of source. None of those exists in September 2026.
What to Ask before You Pay
Ask four questions, in this order, and get the answers in writing. Which product is it, cord blood, cord tissue, or Wharton’s jelly? What is the post-thaw viability for this lot? Who manufactured it, and can I see the FDA registration? Does the quote cover one injection or a course? A clinic that answers all four plainly is a different operation from one that redirects you to a testimonial page, and our clinic vetting guide turns those answers into a decision. If price is your deciding factor, put your own joint through the stem cell injection cost breakdown before you call anyone about umbilical cord stem cells.
Frequently asked questions
Are stem cells from umbilical cords safe?
Donor screening makes the raw tissue reasonably safe. Every documented injury from these products came from contamination introduced after collection, during processing. In 2018 the CDC traced bloodstream infections, joint infections and epidural abscesses in 12 patients across Texas, Florida and Arizona to a contaminated umbilical cord blood product, and all 12 were hospitalized. Because these products are not FDA approved for joints or IV infusion, no regulator has reviewed the manufacturing of the specific vial a clinic is offering you.
Can you get umbilical cord stem cells in the US?
Yes, clinics across the US sell them, but that availability is not FDA approval. Cord blood products the FDA has licensed are for rebuilding blood and immune systems in people with blood disorders. Arthritis, pain, autism and anti-aging are not on that list, so an umbilical cord injection sold for a knee is an unapproved product being sold anyway.
What are the disadvantages of umbilical cord stem cells?
The cells are not yours, so you are trusting a donor screening and manufacturing process you cannot inspect. A 2020 study in the journal Cartilage ran the full proteome on nine commercial birth-tissue products from four manufacturers and found no live cells in any of them. They also cost more than same-day bone marrow or fat procedures because of the screening, lab processing, and shipping, and no insurer covers any of it.
How much does a Wharton's jelly injection cost?
Expect it at the upper end of the $3,000 to $8,000 per joint range US clinics charge for stem cell injections, because donor screening and lab processing are priced into every vial. Ask whether the quote covers one injection or a course of several, because a course of two or three doubles or triples the total.
Is Wharton's jelly covered by insurance?
No. Insurers, Medicare and Medicaid classify umbilical cord and Wharton's jelly injections as experimental, so you pay the full amount yourself. Some clinics accept HSA or FSA funds, which changes who holds the money but not the price.
Medical disclaimer. Medical Frontier is an independent educational resource. This page is for general information only and is not medical advice, diagnosis, or treatment, and does not create a doctor–patient relationship. Most regenerative therapies discussed here are not FDA-approved for the uses described and may be offered under limited exemptions or in clinical trials only. Always consult a licensed physician before making any treatment decision.